BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33045493)

  • 21. [Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis].
    Trenou KC; Mésidor M; Diorio C; Eslami A; Talbot D
    Bull Cancer; 2024 Apr; 111(4):356-362. PubMed ID: 38453587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
    Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
    Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
    Dent SF; Gaspo R; Kissner M; Pritchard KI
    Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
    Paepke S; Jacobs VR; Ohlinger R; Warm M; Kümmel S; Thomas A; Harbeck N; Kiechle-Bahat M
    J Cancer Res Clin Oncol; 2007 Dec; 133(12):905-16. PubMed ID: 17805570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
    Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of aromatase inhibitor therapy in breast cancer.
    Lintermans A; Neven P
    Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibitors and mood disturbances.
    Rocha-Cadman X; Massie MJ; Du Hamel K
    Palliat Support Care; 2012 Sep; 10(3):225-7. PubMed ID: 22677000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia.
    Choo SB; Saifulbahri A; Zullkifli SN; Fadzil ML; Redzuan AM; Abdullah N; Bustamam RSA; Ahmad HZ; Shah NM
    Climacteric; 2019 Apr; 22(2):175-181. PubMed ID: 30556740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.
    Kudachadkar R; O'Regan RM
    CA Cancer J Clin; 2005; 55(3):145-63. PubMed ID: 15890638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
    Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
    J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.